Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Vraylar® (cariprazine) – New indication
December 16, 2022 - AbbVie announced the FDA approval of Vraylar (cariprazine), as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.
